Groundbreaking cancer research: Researchers develop vaccination against lung cancer. Using similar technology to the Oxford/AstraZeneca COVID-19 vaccine, the LungVax vaccine activates the immune system to kill cancer cells.
The vaccine trains the immune System to recognize certain proteins in lung cancer cells and eliminate them. To advance its development, the researchers received 1.7 million pounds (approx. 1.98 million euros) The vaccine is being developed to stop it developing in people at high risk and could cover about 90 percent of lung cancer cases.